{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:38:16Z","timestamp":1787071096900,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>Previous studies have discovered a high expression rate of Mucin 1 (MUC1) in pancreatic cancer tissue, and its abnormal glycosylation causes MUC1 to expose new protein epitopes or glycoantigens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To investigate the therapeutic effect of drug-loaded gemcitabine polybutylcyanoacrylate nanoparticles coupled with anti-human MUC1 monoclonal antibody (mAb) on human pancreatic cancer cell line and xenografts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings and Design:<\/jats:title>\n                    <jats:p>Randomized controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Gemcitabine-loaded nanospheres were prepared by emulsion polymerization; then, the anti-MUC1 mAb coupled with gemcitabine polybutylcyanoacrylate nanoparticles (MUC1-GEM-PBCA-NP) was prepared by chemical cross-linking. Cell-killing rates were detected by MTT assay in\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      study, and changes in tumor cell cycle and apoptosis after treatment were detected by flow cytometry. Furthermore, in\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      study, MUC1-GEM-PBCA-NP was injected into nude mice through the tail vein. Gemcitabine-loaded polybutylcyanoacrylate nanoparticles (GEM-PBCA-NP), gemcitabine bulk drug and empty nanoparticles (PBCA-NP), and normal saline blank control groups were established. Finally, data obtained were compared between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Compared with the control group, the cell-killing rate of each experimental group was significantly different (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05) in\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      study, among which the MUC1-GEM-PBCA-NP group was significantly higher than other groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). In addition, the apoptosis rate of the MUC1-GEM-PBCA-NP treatment group was significantly higher than that of other groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Furthermore, in\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      study, the tumor inhibition rate of the MUC1-GEM-PBCA-NP treatment group was (68.14% \u00b11.66%), which was significantly higher than other control groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Finally, at the end of the treatment, the average tumor mass of the MUC1-GEM-PBCA-NP treatment group was (471.61 mg \u00b1 12.16 mg), which was significantly lower than those of other control groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>MUC1-GEM-PBCA-NP could have an excellent inhibitory effect on tumors; thus, requiring further study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_627_21","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T06:31:13Z","timestamp":1646807473000},"page":"1702-1708","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["A study on the antitumor effect of gemcitabine polybutylcy- anoacrylate nanoparticles coupled with Mucin 1 monoclonal antibody on pancreatic cancer in vitro and in vivo"],"prefix":"10.4103","volume":"17","author":[{"given":"Lin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haorun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-17-20241021","first-page":"1464","article-title":"The preparation and tissue distributions of indocyanine green polybutylcyanoacrylate nanoparticle","volume":"24","author":"Chunmei","year":"2015","journal-title":"Chin J Gastroenterol Hepatol"},{"key":"R3-17-20241021","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.11569\/wcjd.v23.i12.1890","article-title":"Targeted delivery of gemcitabine to pancreatic adenocarcinoma using anti- EGFR antibody as a targeting agent","volume":"23","author":"Li","year":"2015","journal-title":"World Chin J Digestol"},{"key":"R4-17-20241021","first-page":"923","article-title":"Significance of mucin 1 expression in pancreatic cancer tissues","volume":"14","author":"Zhiqiang","year":"2006","journal-title":"World Chin J Digestol"},{"key":"R5-17-20241021","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1007\/s00535-003-1224-6","article-title":"Increased expression of MUC1 in advanced pancreatic cancer","volume":"38","author":"Hinoda","year":"2003","journal-title":"J Gastroenterol"},{"key":"R6-17-20241021","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000086956","article-title":"What makes MUC1 a tumor antigen?","volume":"26","author":"Karsten","year":"2005","journal-title":"Tumour Biol"},{"key":"R7-17-20241021","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/pros.20372","article-title":"Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas","volume":"66","author":"Singh","year":"2006","journal-title":"Prostate"},{"key":"R8-17-20241021","first-page":"281","article-title":"Expression of tumor associated antigens CA 15-3 and CA 19-9 in trophoblast of the normal human placenta","volume":"33","author":"Boji\u0107-Trbojevi\u0107","year":"2012","journal-title":"Eur J Gynaecol Oncol"},{"key":"R9-17-20241021","first-page":"31","article-title":"Synergistic anti-gastric cancer effect and mechanism of Newcasatle Diease virusin combination with gastric cancer antigen loaded dendritic cells","volume":"49","author":"Lin","year":"2009","journal-title":"Shandong Med J"},{"key":"R10-17-20241021","first-page":"695","article-title":"Effect of cinobufotalin inhibiting pancreatic cancer by bioluminescent imaging in the Bx PC3-luc2 cell xenograft nude mice","volume":"39","author":"Jianchao","year":"2015","journal-title":"J Zhejiang Univ Tradit Chin Med"},{"key":"R11-17-20241021","first-page":"1","article-title":"Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2018","volume":"29","author":"Chao","year":"2019","journal-title":"China Oncol"},{"key":"R12-17-20241021","first-page":"1105","article-title":"Analysis of the advances in pancreatic cancer research from 2017 annual meeting of Chinese Society of Clinical Oncology","volume":"16","author":"Wenyan","year":"2017","journal-title":"Chin J Dig Surg"},{"key":"R13-17-20241021","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/biomedicines9020178","article-title":"Therapeutic status and available strategies in pancreatic ductal adenocarcinoma","volume":"9","author":"Thakur","year":"2021","journal-title":"Biomedicines"},{"key":"R14-17-20241021","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1200\/JCO.2021.39.3_suppl.457","article-title":"Gastrointestinal cancer mortality rate global trends over the last century","volume":"39","author":"Sidhu","year":"2021","journal-title":"J Clin Oncol"},{"key":"R15-17-20241021","first-page":"1","article-title":"Gemcitabine inhibits proliferation and induces apoptosis in human pancreatic cancer PANC-1 cells","volume":"2","author":"Gui","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"R16-17-20241021","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4103\/jcrt.JCRT_773_18","article-title":"Irreversible electroporation and adjuvant chemoradio- therapy for locally advanced pancreatic carcinoma","volume":"16","author":"Xu","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"R17-17-20241021","doi-asserted-by":"crossref","first-page":"733","DOI":"10.4103\/0973-1482.126474","article-title":"Intractable nausea in a patient with synchronous pancreatic cancer and a fourth-ventricular ependymoma","volume":"9","author":"Chowdhry","year":"2013","journal-title":"J Cancer Res Ther"},{"key":"R18-17-20241021","first-page":"389","article-title":"Research of nanoparticle targeted therapy for pancreatic cancer","volume":"24","author":"Chunmei","year":"2015","journal-title":"Chin J Gastroenterol Hepatol"},{"key":"R19-17-20241021","first-page":"39","article-title":"Killing effect of nanoparticles formed by brushed polyphosphate encapsulating doxorubicin on pancreatic cancer BxPC-3 cell line","volume":"54","author":"Xixi","year":"2019","journal-title":"Acta Univ Med Anhui"},{"key":"R20-17-20241021","first-page":"3423","article-title":"Expression of MUC1, MUC2, MUC5AC and TFF1 in intraductal papillary mucinous neoplasms of the pancreas and its significance","volume":"15","author":"He","year":"2007","journal-title":"World Chin J Digestol"},{"key":"R21-17-20241021","first-page":"721","article-title":"MUC1 Mucin 1 antibody marked superparamagneticiron oxide nanoparticles in nude mice model of pancreatic cancer: An experimental study","volume":"25","author":"Zhongjie","year":"2017","journal-title":"Chin J Med Imaging"},{"key":"R22-17-20241021","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.canlet.2016.11.030","article-title":"Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy","volume":"388","author":"Zhu","year":"2017","journal-title":"Cancer Lett"},{"key":"R23-17-20241021","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2014.11.005","article-title":"Nanotoxicity of poly (n-butylcyano-acrylate) nanoparticles at the blood-brain barrier, in humanwhole blood and in vivo","volume":"197","author":"Kolter","year":"2015","journal-title":"J Control Release"},{"key":"R24-17-20241021","first-page":"339","article-title":"Box-Behnken optimization design and enhanced oralbioavailability of thymopentin-loaded poly (butylcyanoacrylate) nanoparticles","volume":"66","author":"Jin","year":"2011","journal-title":"Pharmazie"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_627_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:41:24Z","timestamp":1787067684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_627_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_627_21","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}